Legend Biotech Corporation (LEGN)
NASDAQ:LEGN
Want to see LEGN full AI Analyst Report?
Total Valuation
Legend Biotech has a market cap or net worth of $5.12B. The enterprise value is $4.73B.
Market Cap$5.12B
Enterprise Value$4.73B
Share Statistics
Legend Biotech has 184,955,640 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding184,955,640
Owned by Insiders0.13%
Owned by Institutions23.47%
Financial Efficiency
Legend Biotech’s return on equity (ROE) is -0.30 and return on invested capital (ROIC) is -9.59%.
Return on Equity (ROE)-0.30
Return on Assets (ROA)-0.17
Return on Invested Capital (ROIC)-9.59%
Return on Capital Employed (ROCE)-0.12
Revenue Per Employee395.73K
Profits Per Employee-114.46K
Employee Count2,600
Asset Turnover0.59
Inventory Turnover12.75
Valuation Ratios
The current PE Ratio of Legend Biotech is ―. Legend Biotech’s PEG ratio is -0.21.
PE Ratio―
PS Ratio3.89
PB Ratio4.00
Price to Fair Value4.00
Price to FCF-23.85
Price to Operating Cash Flow-28.44
PEG Ratio-0.21
Income Statement
In the last 12 months, Legend Biotech had revenue of 1.03B and earned -296.80M in profits. Earnings per share was -1.60.
Revenue1.03B
Gross Profit620.80M
Operating Income-136.50M
Pretax Income-282.60M
Net Income-296.80M
EBITDA-232.30M
Earnings Per Share (EPS)-1.60
Cash Flow
In the last 12 months, operating cash flow was -175.24M and capital expenditures -61.12M, giving a free cash flow of -236.36M billion.
Operating Cash Flow-175.24M
Free Cash Flow-236.36M
Free Cash Flow per Share-1.28
Dividends & Yields
Legend Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.87
52-Week Price Change-10.28%
50-Day Moving Average21.71
200-Day Moving Average26.27
Relative Strength Index (RSI)58.16
Average Volume (3m)2.67M
Important Dates
Legend Biotech upcoming earnings date is Aug 18, 2026, After Close (Confirmed).
Last Earnings DateMay 12, 2026
Next Earnings DateAug 18, 2026
Ex-Dividend Date―
Financial Position
Legend Biotech as a current ratio of 1.96, with Debt / Equity ratio of 40.23%
Current Ratio1.96
Quick Ratio1.91
Debt to Market Cap0.08
Net Debt to EBITDA2.10
Interest Coverage Ratio-6.38
Taxes
In the past 12 months, Legend Biotech has paid 14.20M in taxes.
Income Tax14.20M
Effective Tax Rate-0.05
Enterprise Valuation
Legend Biotech EV to EBITDA ratio is -15.15, with an EV/FCF ratio of -20.94.
EV to Sales3.42
EV to EBITDA-15.15
EV to Free Cash Flow-20.94
EV to Operating Cash Flow-35.03
Balance Sheet
Legend Biotech has $834.63M in cash and marketable securities with $389.31M in debt, giving a net cash position of $445.31M billion.
Cash & Marketable Securities$834.63M
Total Debt$389.31M
Net Cash$445.31M
Net Cash Per Share$2.41
Tangible Book Value Per Share$5.03
Margins
Gross margin is 53.60%, with operating margin of -13.27%, and net profit margin of -28.85%.
Gross Margin53.60%
Operating Margin-13.27%
Pretax Margin-27.47%
Net Profit Margin-28.85%
EBITDA Margin-22.58%
EBIT Margin-25.39%
Analyst Forecast
The average price target for Legend Biotech is $55.90, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$55.90
Price Target Upside164.06% Upside
Analyst ConsensusStrong Buy
Analyst Count11
Revenue Growth Forecast56.70%
EPS Growth Forecast-13.77%